JPMorgan Thinks This Pot Stock Is a “Clear Leader”

By Daniel Liberto

The brokerage predicted that GW Pharmaceuticals’ cannabis-derived drug Epidiolex will eventually surpass $1 billion in annual sales. …read more

Read more here: JPMorgan Thinks This Pot Stock Is a “Clear Leader”

Category: GWPH, ZGNX

Leave a Reply

%d bloggers like this: